Oruka Therapeutics (ORKA) Share-based Compensation (2010 - 2026)

Oruka Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 42.7% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $26.3 million (down 7.64% YoY), while the FY2025 annual figure was $24.2 million, down 16.7% from the prior year.
• Share-based Compensation for Q1 2026 stood at $7.0 million, up from $4.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.9 million in Q4 2024, with the low at $97000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $204000.0 (2023), against an average of $3.3 million.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 70.94% in 2022, then soared 9784.4% in 2024.
• Oruka Therapeutics' Share-based Compensation stood at $120000.0 in 2022, then grew by 17.5% to $141000.0 in 2023, then jumped by 9784.4% to $13.9 million in 2024, then plunged by 70.47% to $4.1 million in 2025, then jumped by 69.33% to $7.0 million in 2026.
• Business Quant data shows ORKA's Share-based Compensation at $7.0 million in Q1 2026, $4.1 million in Q4 2025, and $10.2 million in Q3 2025.